	4 PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTORNEY 'S DOCKET NUMBER							
TRANSMITTAL LETTER TO THE UNITED STATES			ATEC	3039 US0P							
•	DESIGNATED/ELECT		U.S. APPLICATION NO. (14 known, see 17 CTA) 1.52								
DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371											
INTER	NATIONAL APPLICATION NO.	INTERNATIONAL FILING D	DATE	PRIORITY DATE CLAIMED							
	/JP03/04396	April 7, 2003		April 8, 2002							
	TITLE OF INVENTION SEVERE SEPSIS PREVENTIVE THERAPEUTIC AGENT										
	CANT(S) FOR DO/EO/US	AKI Kazuki KHRO									
Masayuki II, Yuji IIZAWA, Tomoyuki KITAZAKI, Kazuki KUBO Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:											
1.	1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.										
2.	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.										
3. 🔲	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.										
_	The US has been elected (Article 31).										
5. X	A copy of the International Application as filed (35 U.S.C. 371(c)(2))										
	is attached hereto (required only if not communicated by the International Bureau).										
	 b. has been communicated by the International Bureau. c. is not required, as the application was filed in the United States Receiving Office (RO/US). 										
6. 🕱	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).										
	a. is attached hereto.										
	b. has been previously submitted under 35 U.S.C. 154(d)(4).										
7. 🗶	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))										
		ed only if not communicated by t	he Internation	onal Bureau).							
	b. have been communicated by the International Bureau.										
	c. have not been made; howe	have not been made; however, the time limit for making such amendments has NOT expired.									
	d. kave not been made and will not be made.										
8.	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).										
9. 🔲	An oath or declaration of the invento	or(s) (35 U.S.C. 371(c)(4)).									
10.	An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).										
Items 11 to 20 below concern document(s) or information included:											
11. 🗶	An Information Disclosure Statement under 37 CFR 1.97 and 1.98. Cited References										
12. 🔲	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.										
13. 🗶	A preliminary amendment.										
14.	An Application Data Sheet under 37 CFR 1.76.										
15.	A substitute specification.										
16.	A power of attorney and/or change of address letter.										
17.	A computer-readable form of the s	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.									
18.	A second copy of the published in	A second copy of the published international application under 35 U.S.C. 154(d)(4).									
19. 🔲	A second copy of the English lang	uage translation of the internation	nal applicati	on under 35 U.S.C. 154(d)(4).							
20. 🗶	Other items or information: \$\int_600Itemized Return Postcard; Certificate of			il Label No. 524906075 US							
	PCT Request; Forms PCT/IB/301, 304	_	•	osit October 7 , 2004							
	International Application; ISR										

U.S. APPLICATION NO. (II ID	ATTORNEY'S DOCKET NUMBER 3039 USOP								
21. The follow	ing fees are submitted:	PCT/JP03/04396		CAL	CULATIONS F	TO USE ONLY			
	FEE (37 CFR 1.492 (a)								
Neither internation	al preliminary examinat earch fee (37 CFR 1.445) earch Report not prepare								
International prelin	ninary examination fee ((37 CFR 1.482) not paid to epared by the EPO or JPO							
International prelin but international se	ninary examination fee (earch fee (37 CFR 1.445)								
International prelin but all claims did n	ninary examination fee (oot satisfy provisions of l								
and all claims satis	ninary examination fee (fied provisions of PCT A R APPROPRIATE	<u>s</u>	950.00						
	0 for furnishing the oath	3	950.00	. <u> </u>					
from the earliest cla	imed priority date (37 Cl	\$	0						
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$		-			
Total claims	20 - 20 =	0	x \$18.00	\$	0				
Independent claims	10 -3 =	7	x \$ 85 .00	\$	616.00				
MULTIPLE DEPEN	DENT CLAIM(S) (if ap		+ \$290.00	\$	0				
		OF ABOVE CALCU		\$	0	<u> </u>			
Applicant claim are reduced by	ns small entity status. Se 1/2.	\$	0						
- · · · · · · · · · · · · · · · · · · ·		\$	1,566.00						
from the earliest cla	30.00 for furnishing the imed priority date (37 C	\$	0						
		\$	1,566.00						
ree for recording the accompanied by an	e enclosed assignment (3 appropriate cover sheet (\$	40.00						
	\$	1,606.00							
					ount to be refunded:	\$			
					charged:	\$			
 a. A check in the amount of \$ to cover the above fees is enclosed. b. Please charge my Deposit Account No. 500799 in the amount of \$ 1.606.00 to cover the above fees. A duplicate copy of this sheet is enclosed. c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 500799 . A duplicate copy of this sheet is enclosed. d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card 									
NOTE: Where an	appropriate time limit	ed on this form. Provide of tunder 37 CFR 1.495 has re the application to pend	s not been met, a pe						
SEND ALL CORRESPO		4	The f	>					
Mark Chao, PhD, JD					JRE .				
Takeda	Pharmaceuticals	Chao, PhD, JD							
475 Ha	lf Day Road								
	shire, IL 60069 L	37,293							
		ATION NUMBER							
(041)383-	3372 fax (847)383-34	Customer No. 23,115							



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 10596

Application No.:

Based on PCT/JP03/04396

Filed:

Intl. Filing 07 APRIL 2003

1st Inventor:

II, Masayuki

For:

Severe Sepsis Preventive Therapeutic Agent

Atty. Dkt. No.

3039 US0P

Art Unit:

tba

Examiner:

tba

Allowed:

Batch:

Paper No.:

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EV 524906075 US

DATE IN:

October 7, 2004

Itemized Papers/Items:

- 1. This Certificate and Return Postcard (2 pages)
- 2. Transmittal Letter for Filing under 35 USC 371 (2 pages X 2)
- 3. Specification total pages (122) including Claims 1-20 (pages 107-115, Abstract (1 page), and Drawings (6 pages)
- 4. PCT Request (5 pages)
- 5. Copies of Forms PCT/IB/301, 304, 308 (4 pages)
- 6. Copy of Cover Page International Application (WO 03/084527) (1 page)
- 7. Copy of International Search Report (4 pages)
- 8. Preliminary Amendment (3 pages)
- 9. Information Disclosure Statement (1 page), Form PTO/SB/08A and 08B (3 pages), cited references (10)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

MAIL STOP PCT P.O. BOX 1450 Commissioner for Patents

Alexandria, VA 22313-1450

on this date, 10/7/04

Dated: 10/7/04

Dawn Hackbert

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department 475 Half Day Road Lincolnshire, IL 60069 USA